inflammatory%20bowel%20disease
INFLAMMATORY BOWEL DISEASE
Inflammatory bowel disease consists of ulcerative colitis and Crohn's disease.
Ulcerative colitis is a diffuse mucosal inflammation limited to the colon while Crohn's disease is a patchy, transmural inflammation that occurs in any part of the gastrointestinal tract.
The ileum and colon are the most frequently affected sites.

Introduction

  • Consists of ulcerative colitis (UC) and Crohn’s disease (CD)
    • UC: Diffuse mucosal inflammation limited to the colon
    • CD: Patchy, transmural inflammation that can occur in any part of the GI tract
      • Ileum and colon are the most frequently affected sites

Signs and Symptoms

General Symptoms

Depend on the segment of the intestinal tract involved

  • Chronic diarrhea or constipation
  • Abdominal pain and cramps
  • Blood in stool
  • Pain with bowel movement
  • Urgency in bowel movement
  • Tenesmus
  • Reduced appetite
  • Weight loss
  • Fever
  • Fatigue
  • Growth retardation
  • Primary amenorrhea
  • Night sweats

Clinical Features

Ulcerative Colitis (UC)

  • Cardinal symptoms: Bloody diarrhea, frequent, small volume
  • Associated symptoms: Colicky abdominal pain, tenesmus, urgency

Crohn's Disease (CD)

  • Chronic diarrhea, abdominal pain, weight loss
  • Abdominal mass, perianal lesions, stomatitis, fissures and fistulas
  • Malaise, fever, anorexia are more common with CD than UC

Risk Factors

Risk Factors

  • Smoking is a risk factor for CD but has a protective factor for UC through unknown mechanism
  • Age - most people are diagnosed between 15 and 35 years
  • UC is more common in men while CD is more frequent in women
  • Family history
  • Recent episodes of infectious gastroenteritis
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Gastroenterology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
01 May 2014

New drug applications approved by US FDA as of 15-30 May which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

28 Apr 2017
Silymarin does not appear to be significantly better than placebo in reducing disease activity by 30 percent or more in patients with nonalcoholic steatohepatitis (NASH), according to the results of a trial.
08 May 2017
Transabdominal bowel wall ultrasonography shows utility in monitoring disease activity in patients with active Crohn’s disease (CD), according to a study. The imaging technique is ideal for evaluating early transmural changes in disease activity, in response to medical treatment.